Cover Image
市場調查報告書

中風的診斷和治療:全球市場

Stroke Diagnostics and Therapeutics: Global Markets

出版商 BCC Research 商品編碼 325325
出版日期 內容資訊 英文 161 Pages
訂單完成後即時交付
價格
Back to Top
中風的診斷和治療:全球市場 Stroke Diagnostics and Therapeutics: Global Markets
出版日期: 2015年03月04日 內容資訊: 英文 161 Pages
簡介

全球中風管理市場規模2013年是192億美元,2014年約202億美金。該市場預計從2014年到2019年以7%的年複合成長率發展,到2019年達到283億美元。

本報告提供全球中風治療、診斷市場相關調查、市場概要、實際成果資料和年複合成長率預測的市場趨勢分析、市場影響因素、主要市場課題、趨勢、機會確認與分析,及主要企業與產品系列相關總括的簡介等彙整資料,為您概述為以下內容。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 中風、中風的分類
  • 發病率、罹患率
  • 中風臨床診斷
  • 治療性介入
  • 技術開發:生物標記與風險預測、診斷所扮演的角色
  • 供應鏈流程、市場分析
  • 地區市場分析:已開發國家 vs. 新興國家
  • 法規,政府政策,環境淨空,CE標誌/FDA 認證、其他
  • 案例研究、概要:新的設備為基礎的血管內療法
  • 市場情報
  • 市場動態
  • 新的血管內療法系統
  • 現狀、未來趨勢
  • 分析、結論、建議

第4章 中風診斷、管理設備市場

  • 中風診斷

第5章 中風的治療管理

  • 抗凝固療法
  • 降壓劑療法
  • 抗血小板藥療法
  • 其他藥劑療法
  • 主要的中風管理藥 (遺傳基因) 分析
  • 中風相關的特殊、血管內介入

第6章 市場:中風的各類型

  • 出血性
  • 缺血性

第7章 中風管理市場:各相關利益者

  • 供應鏈的成員
  • 終端用戶

第8章 競爭環境

  • 認證
  • 產品銷售

第9章 地區分析

  • 北美
  • 歐洲
  • 亞洲
  • 其他

第10章 專利分析

  • 美國的專利分析
  • 歐洲的專利分析
  • 日本的專利分析

第11章 企業簡介

  • ABBOTT VASCULAR
  • B BRAUN MELSUNGEN AG
  • BOSTON SCIENTIFIC CORP.
  • BRISTOL-MYERS SQUIBB
  • COAXIA INC.
  • CORDIS CORP.
  • GE HEALTHCARE
  • GENENTECH INC.
  • GLAXOSMITHKLINE PLC.
  • MERCK & COMPANY
  • MIZUHO AMERICA INC.
  • PHILIPS HEALTHCARE
  • SIEMENS HEALTHCARE

第12章 附錄

圖表清單

目錄
Product Code: HLC180A

The global stroke management market was valued at $19.2 billion in 2013 and nearly $20.2 billion in 2014. This market is expected to reach nearly $28.3 billion by 2019, with a compound annual growth rate (CAGR) of 7% from 2014 to 2019.

This report provides:

  • An overview of the global market for stroke therapeutics and diagnostics.
  • Analyses of market trends, with data from 2013 and 2014, and projections of CAGRs through 2019.
  • Information on the major factors driving and inhibiting growth of the global stroke diagnostics market and its products.
  • Identification and analysis of key market issues, trends, gaps, and opportunities within the market as well the market's sub-segments.
  • Comprehensive profiles of key companies and their product portfolios, and recent developments.

image1

REPORT SCOPE

SCOPE OF THE REPORT

The report on global stroke diagnostics and management products market includes forecasts, trends and estimated sales through 2019. The report discusses in detail the market dynamics and the level of impact, key geographies and respective trends, competitive scenario that would form the base data for qualitative analysis and market estimates.

The global stroke diagnostics and management products market has been analyzed for the four main geographies of North America, Europe, Asia-Pacific and ROW. Given that the facilities available to patients vary depending on geography this is likely to have a direct impact on potential markets.

The report will discuss the various techniques used for stroke diagnostics (e.g. diagnostics imaging and magnetic resonance imaging) in detail. It will also analyze the therapeutic management of stroke (e.g. pharmacologic therapeutic modalities, stroke-related surgical and endovascular interventions). The discussions will mostly focus on what these techniques entail, expected volumes and innovations. In addition, the report investigates the various stroke management products - and how they are associated with the patient's medical condition - and will focus on different types of products (e.g. computed tomography systems, diagnostic ultrasound systems) and related market forecasts and competitive analysis.

ANALYST'S CREDENTIALS

Bhavna Joshi has more than six years of domain experience. In addition to business research and consulting, she has conducted corporate briefings for top players in a wide range of market segments. She holds an MBA in marketing and finance from Chennai University and has worked with major market research firms.

Bhavna has authored several market research studies on subjects in the healthcare domain, including:

  • Healthcare tracking technologies.
  • Molecular diagnostics market.
  • High-growth markets in healthcare and life sciences.
  • Adoption rates and analysis of over-the-counter (OTC) diabetic medicines and supplements.
  • Radio frequency identification (RFID), real-time locating systems (RTLS), Internet protocol (IP) surveillance and other emerging technologies in the healthcare domain.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY AND OBJECTIVE
  • STUDY BACKGROUND
  • SCOPE OF THE REPORT
  • INTENDED AUDIENCE
  • SOURCE OF INFORMATION AND METHODOLOGY
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 EXECUTIVE SUMMARY

  • SUMMARY TABLE GLOBAL STROKE MANAGEMENT MARKET, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL STROKE MANAGEMENT MARKET, 2013-2019 ($ MILLIONS)

CHAPTER 3 MARKET OVERVIEW

  • STROKE AND CLASSIFICATION OF STROKE
    • ISCHEMIC
    • HEMORRHAGIC
  • INCIDENCE AND PREVALENCE RATES
  • FIGURE 1 TOP 10 LEADING CAUSES OF DEATH IN THE WORLD, 2012 (MILLIONS)
  • TABLE 1 RISK FACTORS OF STROKE
  • FIGURE 2 NUMBER OF STROKES IN THE WORLD, 1990-2010 (MILLIONS)
  • FIGURE 3 GLOBAL INCIDENCE AND PREVALENCE OF STROKE BY REGION, 2010 (%)
  • TABLE 2 PREVALENCE OF STROKE IN THE U.K. BY REGION AND GENDER, 2010 (%)
  • TABLE 3 TOTAL NUMBER OF DEATHS FROM STROKE IN THE U.K. BY REGION, 2010 (NUMBER)
  • FIGURE 4 U.S. PREVALENCE OF STROKE BY AGE AND GENDER IN PERCENTAGE OF POPULATION, 2010 (%)
  • CLINICAL DIAGNOSIS OF STROKE
  • FIGURE 5 ALGORITHM FOR THE DIAGNOSIS OF ACUTE STROKE
    • COMPUTED TOMOGRAPHY
    • MAGNETIC RESONANCE IMAGING (MRI)
    • CAROTID ULTRASOUND
    • CAROTID ANGIOGRAPHY
    • ELECTROCARDIOGRAM
    • ECHOCARDIOGRAPHY
    • BLOOD TESTS
  • THERAPEUTIC INTERVENTION
    • CAROTID ENDARTERECTOMY
    • THROMBOLYSIS
  • TECHNOLOGY DEVELOPMENTS - ROLE OF BIOMARKERS, RISK PREDICTION AND DIAGNOSIS
    • DISCOVERING BIOMARKERS FOR STROKE
    • APPLICATIONS OF BIOMARKERS IN STROKE RESEARCH
    • TABLE 4 ROLE OF BIOMARKERS
      • High-risk Subjects
      • Stroke Prediction
      • Possible Stroke Mechanisms
      • Drug Response and Outcome
      • Surrogate Endpoints
    • TYPE OF BIOMARKERS IN STROKE RESEARCH
    • TABLE 5 BIOMARKERS FOR SPECIFIC STROKE SUBTYPES
      • Protein Biomarkers
      • Genetic biomarkers
      • Microvesicle
      • Metabolomics
    • LIMITATIONS OF STROKE BIOMARKERS
    • TABLE 6 ADVANTAGES AND DISADVANTAGES OF BIOMARKERS BY TYPE
    • TABLE 7 POST STROKE DISEASE MANAGEMENT - CLINICAL TRIAL
    • TABLE 8 CLINICAL TRIAL: A SELF-EFFICACY ENHANCING STROKE SELF-MANAGEMENT PROGRAM FOR COMMUNITY-DWELLING STROKE SURVIVORS (SESSMP)
    • TABLE 9 CLINICAL TRIAL: ADAPTIVE PHYSICAL ACTIVITY FOR CHRONIC STROKE
    • TABLE 10 CLINICAL TRIAL: TAILORED APPROACHES TO STROKE HEALTH EDUCATION (TASHE)
    • TABLE 11 CLINICAL TRIAL: PROSPECTIVE STROKE COHORT
  • SUPPLY CHAIN PROCESS AND MARKET ANALYSIS
  • FIGURE 6 SUPPLY CHAIN ANALYSIS - STROKE DIAGNOSIS AND MANAGEMENT
  • FIGURE 7 FACTORS THAT INFLUENCE THE QUALITY OF THE STROKE MANAGEMENT SUPPLY CHAIN
  • GEOGRAPHIC MARKET ANALYSIS: DEVELOPED VERSUS DEVELOPING ECONOMIES
  • TABLE 12 HEALTHCARE EXPENDITURE COMPARISON, DEVELOPED VERSUS DEVELOPING ECONOMIES, 2008-2012* (% OF GDP)
  • REGULATIONS, GOVERNMENT POLICIES, ENVIRONMENT CLEARANCES, CE MARK/FDA APPROVALS ETC
    • GOVERNMENT REGULATIONS - POLICY CHANGES TO IMPROVE STROKE CARE, U.S.
    • NATIONAL SUMMARY OF STATE POLICY AND REGULATION
    • FIGURE 8 TIMELINE FOR ENACTMENT OF PRIMARY STROKE CENTER LEGISLATIVE OR NON-LEGISLATIVE POLICY, JULY 2010
      • Type of Policy
    • CDC FUNDING
      • National Heart Disease and Stroke Prevention Program
      • Paul Coverdell National Acute Stroke Registry
      • Stroke Networks
    • NATIONAL STROKE STRATEGY, U.K.
    • CE MARK/FDA APPROVALS
  • CASE STUDIES AND BRIEF: EMERGING DEVICE-BASED ENDOVASCULAR THERAPIES
    • CEREBRAL EMBOLECTOMY/THROMBECTOMY SYSTEMS- CONCENTRIC MEDICAL
    • MERCI RETRIEVER
    • PATIENT ENROLMENT FOR CLINICAL TRIALS - TREVO 2 IN FEBRUARY, 2011
    • EKOS
      • Aim
      • Methods
      • Results
      • Discussion
      • Conclusion
    • FDA APPROVAL OF BOSTON SCIENTIFIC'S STROKE FIGHTING DEVICE
    • EV3 - COMPARISON OF TWO STROKE DEVICES: APERIO CLOT REMOVAL AND EV3'S - SOLITAIRE AB/FR
      • Background
      • Materials and Methods
      • Results
      • Discussion
    • MICRUS ENDOVASCULAR - EFFECTIVENESS OF MICRUS ENDOVASCULAR PHAROS ON A PATIENT
      • Clinical History
      • Technology Involved
      • Conclusion
    • BRAINSGATE - FDA APPROVAL ON ITS STROKE TREATMENT STUDY
      • BrainsGate Changed Stroke Treatment Pivotal Trial Structure in January, 2013
    • COAXIA
      • The SENTIS Stroke Trial
  • MARKET INTELLIGENCE
  • FIGURE 9 RECENT DEVELOPMENTS BY COMPANY, 2011-2014 (NUMBER OF PROJECTS)
  • MARKET DYNAMICS
  • FIGURE 10 GLOBAL POPULATION GROWTH, BY AGE GROUP, 2010-2020 (MILLIONS)
  • EMERGING ENDOVASCULAR THERAPEUTIC SYSTEMS
    • CEREBRAL EMBOLECTOMY/THROMBECTOMY SYSTEMS
    • INTRACRANIAL STENTING SYSTEMS
    • CEREBRAL PERFUSION AUGMENTATION SYSTEMS
  • CURRENT SCENARIO AND FUTURE TRENDS
  • ANALYSIS, CONCLUSIONS AND RECOMMENDATIONS

CHAPTER 4 STROKE DIAGNOSTIC AND MANAGEMENT DEVICES MARKET

  • STROKE DIAGNOSTICS
    • DIAGNOSTIC IMAGING
    • TABLE 13 GLOBAL STROKE DIAGNOSTIC IMAGING MARKET, THROUGH 2019 ($ MILLIONS)
    • TABLE 14 GLOBAL STROKE DIAGNOSTIC IMAGING MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
      • Computed Tomography
      • TABLE 15 GLOBAL COMPUTED TOMOGRAPHY MARKET BY SYSTEM, THROUGH 2019 ($ MILLIONS)
      • TABLE 16 GLOBAL COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 $ MILLIONS)
        • Spiral Computed Tomography 68
        • TABLE 17 GLOBAL SPIRAL COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
        • Multislice Computed Tomography
        • TABLE 18 GLOBAL MULTISLICE COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
        • Dual Source Multislice CT
        • TABLE 19 GLOBAL DUAL SOURCE MULTISLICE COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
        • Computed Tomography Angiography
        • TABLE 20 GLOBAL COMPUTED TOMOGRAPHY ANGIOGRAPHY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
        • Perfusion Computed Tomography
        • TABLE 21 GLOBAL PERFUSION COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
      • Magnetic Resonance Imaging
      • TABLE 22 GLOBAL MRI MARKET BY TYPES, THROUGH 2019 ($ MILLIONS)
      • TABLE 23 GLOBAL MRI MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
        • Magnetic Resonance Angiography
        • TABLE 24 GLOBAL MAGNETIC RESONANCE ANGIOGRAPHY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
        • Time-of-Flight Magnetic Resonance Angiography
        • TABLE 25 GLOBAL TOF-MRA MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
        • Phase-Contrast Magnetic Resonance Angiography
        • TABLE 26 GLOBAL PC-MRA MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
        • Contrast-Enhanced Magnetic Resonance Angiography
        • TABLE 27 GLOBAL CE-MRA MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
        • Functional Magnetic Resonance Imaging
        • TABLE 28 GLOBAL FMRI MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
        • Proton Magnetic Resonance Spectroscopy
        • TABLE 29 GLOBAL PROTON MAGNETIC RESONANCE SPECTROSCOPY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
      • Diagnostic Ultrasound
      • TABLE 30 GLOBAL DIAGNOSTIC ULTRASOUND MARKET, THROUGH 2019 ($ MILLIONS)
      • TABLE 31 GLOBAL DIAGNOSTIC ULTRASOUND MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
        • Doppler Ultrasound
        • TABLE 32 GLOBAL DOPPLER ULTRASOUND MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
        • Duplex Ultrasound
        • TABLE 33 GLOBAL DUPLEX ULTRASOUND MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
      • Cerebral Angiography
      • TABLE 34 GLOBAL CEREBRAL ANGIOGRAPHY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
      • Nuclear Imaging
      • TABLE 35 GLOBAL NUCLEAR IMAGING MARKET, THROUGH 2019 ($ MILLIONS)
      • TABLE 36 GLOBAL NUCLEAR IMAGING MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
        • Gamma Camera Imaging
        • TABLE 37 GLOBAL GAMMA CAMERA IMAGING MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
        • Positron Emission Tomography
        • TABLE 38 GLOBAL PET MARKET BY REGION, THROUGH 2019 ($ MILLIONS)

CHAPTER 5 THERAPEUTIC MANAGEMENT OF STROKE

  • TABLE 39 GLOBAL THERAPEUTIC MANAGEMENT MARKET OF STROKE BY DRUG CATEGORY, THROUGH 2019 ($ MILLIONS)
  • ANTICOAGULATION THERAPY
    • COUMARINS (VITAMIN K ANTAGONISTS)
    • HEPARIN AND DERIVATIVE SUBSTANCES
    • OTHERS
    • TABLE 40 GLOBAL ANTICOAGULATION THERAPY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • ANTIHYPERTENSIVE DRUG THERAPY
  • TABLE 41 GLOBAL ANTIHYPERTENSIVE DRUG THERAPY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • ANTIPLATELET DRUG THERAPY
  • TABLE 42 GLOBAL ANTIPLATELET DRUG THERAPY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • OTHER DRUG THERAPIES
  • TABLE 43 GLOBAL OTHER DRUG THERAPY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • KEY STROKE MANAGEMENT DRUGS (GENERIC) ANALYSIS
  • TABLE 44 GLOBAL STROKE MANAGEMENT DRUG MARKET, THROUGH 2019 ($ MILLIONS)
    • WARFARIN
    • TABLE 45 GLOBAL WARFARIN MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • DABIGATRAN
    • TABLE 46 GLOBAL DABIGATRAN MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • NADROPERIN
    • TABLE 47 GLOBAL NADROPERIN MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • ENAXOPERIN
    • TABLE 48 GLOBAL ENAXOPERIN MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • ATENOLOL
    • TABLE 49 GLOBAL ATENOLOL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • METOPROLOL
    • TABLE 50 GLOBAL METOPROLOL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • PINDOLOL
    • TABLE 51 GLOBAL PINDOLOL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • HYDROCHLOROTHIAZIDE
    • TABLE 52 GLOBAL HYDROCHLOROTHIAZIDE MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • LOSARTAN
    • TABLE 53 GLOBAL LOSARTAN MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • ENALAPRIL
    • TABLE 54 GLOBAL ENALAPRIL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • LISINOPRIL
    • TABLE 55 GLOBAL LISINOPRIL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • FELODIPINE
    • TABLE 56 GLOBAL FELODIPINE MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • ASPIRIN
    • TABLE 57 GLOBAL ASPIRIN MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • DIPYRIDAMOLE
    • TABLE 58 GLOBAL DIPYRIDAMOLE MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • CLOPIDOGREL
    • TABLE 59 GLOBAL CLOPIDOGREL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • ALTEPLASE
  • STROKE-RELATED SURGICAL AND ENDOVASCULAR INTERVENTIONS
  • TABLE 60 GLOBAL STROKE RELATED SURGICAL AND ENDOVASCULAR INTERVENTIONS MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 61 GLOBAL STROKE RELATED SURGICAL AND ENDOVASCULAR INTERVENTIONS MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • TREATMENT OF STROKE-PRONE CAROTID ARTERY STENOSIS
    • TABLE 62 GLOBAL STROKE-PRONE CAROTID ARTERY STENOSIS MARKET, THROUGH 2019 ($ MILLIONS)
    • TABLE 63 GLOBAL STROKE-PRONE CAROTID ARTERY STENOSIS MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
      • Carotid Endarterectomy
      • TABLE 64 GLOBAL CAROTID ENDARTERECTOMY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
      • Carotid Artery Stenting
      • TABLE 65 GLOBAL CAROTID ARTERY STENTING MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • MANAGEMENT OF INTRACRANIAL ANEURYSMS AND ARTERIOVENOUS MALFORMATIONS
    • TABLE 66 GLOBAL INTRACRANIAL ANEURYSMS AND ARTERIOVENOUS MALFORMATIONS MARKET, THROUGH 2019 ($ MILLIONS)
    • TABLE 67 GLOBAL INTRACRANIAL ANEURYSMS AND ARTERIOVENOUS MALFORMATIONS MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
      • Intracranial Aneurysms
      • TABLE 68 GLOBAL INTRACRANIAL ANEURYSMS MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
      • Arteriovenous Malformations
      • TABLE 69 GLOBAL ARTERIOVENOUS MALFORMATIONS MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
      • Surgical Repair
      • TABLE 70 GLOBAL SURGICAL REPAIR MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
      • Endovascular Embolization
      • TABLE 71 GLOBAL ENDOVASCULAR EMBOLIZATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
      • Stereotactic Radiotherapy
      • TABLE 72 GLOBAL STEREOTACTIC RADIOTHERAPY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)

CHAPTER 6 MARKET BY TYPES OF STROKES

  • TABLE 73 GLOBAL STROKES MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • HEMORRHAGIC
    • TABLE 74 GLOBAL HEMORRHAGIC STROKES MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 75 GLOBAL HEMORRHAGIC STROKES MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • INTRACEREBRAL
    • TABLE 76 GLOBAL INTRACEREBRAL STROKES MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • SUBARACHNOID HEMORRHAGE
    • TABLE 77 GLOBAL SUBARACHNOID HEMORRHAGE STROKES MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • ISCHEMIC
  • TABLE 78 GLOBAL ISCHEMIC STROKES MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 79 GLOBAL ISCHEMIC STROKES MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • THROMBOTIC
      • Unmet Medical Need
      • European Companies are the Major Players
      • TABLE 80 GLOBAL THROMBOTIC STROKES MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • EMBOLIC
    • TABLE 81 GLOBAL EMBOLIC STROKES MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • TRANSIENT ISCHEMIC ATTACK (TIA)
    • TABLE 82 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET BY REGION, THROUGH 2019 ($ MILLIONS)

CHAPTER 7 STROKE MANAGEMENT MARKET BY STAKEHOLDERS

  • SUPPLY CHAIN MEMBERS
  • TABLE 83 GLOBAL STROKE MANAGEMENT MARKET BY SUPPLY CHAIN MEMBERS, THROUGH 2019 ($ MILLIONS)
    • MANUFACTURERS
    • TABLE 84 GLOBAL STROKE MANAGEMENT MARKET-MANUFACTURERS, BY REGION, THROUGH 2019 ($ MILLIONS)
    • DISTRIBUTORS
    • TABLE 85 GLOBAL STROKE MANAGEMENT MARKET-DISTRIBUTORS, BY REGION, THROUGH 2019 ($ MILLIONS)
    • SUPPLIERS
    • TABLE 86 GLOBAL STROKE MANAGEMENT MARKET-SUPPLIERS, BY REGION, THROUGH 2019 ($ MILLIONS)
  • END-USERS
  • TABLE 87 GLOBAL STROKE MANAGEMENT MARKET BY END USERS, THROUGH 2019 ($ MILLIONS)
    • LIFE SCIENCES
    • TABLE 88 GLOBAL STROKE MANAGEMENT MARKET-LIFE SCIENCES, BY REGION, THROUGH 2019 ($ MILLIONS)
    • HOSPITALS
    • TABLE 89 GLOBAL STROKE MANAGEMENT MARKET-HOSPITALS, BY SIZE, THROUGH 2019 ($ MILLIONS)
    • TABLE 90 GLOBAL STROKE MANAGEMENT MARKET-HOSPITALS, BY REGION, THROUGH 2019 ($ MILLIONS)
    • DIAGNOSTIC CENTERS
    • TABLE 91 GLOBAL STROKE MANAGEMENT MARKET-DIAGNOSTIC CENTERS, BY REGION, THROUGH 2019 ($ MILLIONS)
    • PATIENTS
    • TABLE 92 GLOBAL STROKE MANAGEMENT MARKET-PATIENTS, BY REGION, THROUGH 2019 ($ MILLIONS)

CHAPTER 8 COMPETITIVE LANDSCAPE

  • FIGURE 11 RECENT DEVELOPMENT BY STRATEGIES, 2011 TO 2014 (NUMBER)
  • CERTIFICATION
  • FIGURE 12 CERTIFICATION BY COMPANIES, 2011 TO 2014 (NUMBER OF CERTIFICATIONS)
  • TABLE 93 RECENT DEVELOPMENT - CERTIFICATION BY COMPANY, 2011 TO 2014
  • PRODUCT LAUNCH
  • FIGURE 13 PRODUCT LAUNCH BY COMPANIES, 2011 TO 2014 (NUMBER OF LAUNCHES)
  • TABLE 94 RECENT DEVELOPMENT-PRODUCT LAUNCH BY COMPANY, 2011 TO 2014

CHAPTER 9 GEOGRAPHIC ANALYSIS

  • NORTH AMERICA
  • TABLE 95 NORTH AMERICAN STROKE MANAGEMENT MARKET, THROUGH 2019 ($ MILLIONS)
  • EUROPE
  • TABLE 96 EUROPE GERIATRIC POPULATION STATISTICS, 1991 AND 2011 (MILLIONS)
  • TABLE 97 EUROPEAN STROKE MANAGEMENT MARKET, THROUGH 2019 ($ MILLIONS)
  • ASIA
  • TABLE 98 ASIA GERIATRIC POPULATION STATISTICS, 2000 AND 2025 (MILLIONS)
  • TABLE 99 ASIAN STROKE MANAGEMENT MARKET, THROUGH 2019 ($ MILLIONS)
  • REST OF THE WORLD
  • TABLE 100 ROW STROKE MANAGEMENT MARKET, THROUGH 2019 ($ MILLIONS)

CHAPTER 10 PATENT ANALYSIS

  • FIGURE 14 GLOBAL PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)
  • U.S. PATENT ANALYSIS
  • FIGURE 15 U.S. PATENTS BY TECHNOLOGY, 2008 TO 2014 (NO. OF PATENTS)
  • FIGURE 16 U.S. PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)
  • EUROPEAN PATENT ANALYSIS
  • FIGURE 17 EUROPEAN PATENTS BY TECHNOLOGY, 2008 TO 2014 (NO. OF PATENTS)
  • FIGURE 18 EUROPEAN PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)
  • JAPAN PATENT ANALYSIS
  • FIGURE 19 JAPAN PATENTS BY TECHNOLOGY, 2008 TO 2014 (NO. OF PATENTS)
  • FIGURE 20 JAPAN PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)

CHAPTER 11 COMPANY PROFILES

  • ABBOTT VASCULAR
  • TABLE 101 ABBOTT VASCULAR'S PRODUCT PORTFOLIO
  • TABLE 102 ABBOTT VASCULAR'S RECENT DEVELOPMENTS, 2011 TO AUG 2014
  • B BRAUN MELSUNGEN AG
  • TABLE 103 B BRAUN'S PRODUCT PORTFOLIO
  • BOSTON SCIENTIFIC CORP.
  • TABLE 104 BOSTON SCIENTIFIC'S PRODUCT PORTFOLIO
  • TABLE 105 BOSTON SCIENTIFIC'S RECENT DEVELOPMENTS, 2011 TO JUNE 2014 152
  • BRISTOL-MYERS SQUIBB 153
  • TABLE 106 BRISTOL MYERS SQUIBB PRODUCT PORTFOLIO
  • TABLE 107 BRISTOL MYERS SQUIBB RECENT DEVELOPMENTS - 2011 TO SEP 2014
  • COAXIA INC.
  • TABLE 108 COAXIA INC PRODUCT PORTFOLIO
  • CORDIS CORP.
  • TABLE 109 CORDIS CORP. PRODUCT PORTFOLIO
  • GE HEALTHCARE
  • TABLE 110 GE HEALTHCARE PRODUCT PORTFOLIO
  • TABLE 111 GE HEALTHCARE RECENT DEVELOPMENTS, 2011 TO AUG 2014
  • GENENTECH INC.
  • TABLE 112 GENENTECH'S PRODUCT PORTFOLIO
  • GLAXOSMITHKLINE PLC.
  • TABLE 113 GLAXOSMITHKLINE PLC PRODUCT PORTFOLIO
  • MERCK & COMPANY
  • TABLE 114 MERCK'S PRODUCT PORTFOLIO
  • TABLE 115 MERCK'S RECENT DEVELOPMENTS 2011 TO SEP 2014
  • MIZUHO AMERICA INC.
  • TABLE 116 MIZUHO AMERICA'S PRODUCT PORTFOLIO
  • PHILIPS HEALTHCARE
  • TABLE 117 PHILIPS HEALTHCARE PRODUCT PORTFOLIO
  • TABLE 118 PHILIPS HEALTHCARE RECENT DEVELOPMENTS, 2011 TO APRIL 2014
  • SIEMENS HEALTHCARE
  • TABLE 119 SIEMENS HEALTHCARE'S PRODUCT PORTFOLIO

CHAPTER 12 APPENDIX

  • UNITED STATES
  • TABLE 120 U.S. PATENT LIST, 2011 TO 2014
  • EUROPE
  • TABLE 121 EUROPEAN PATENT LIST, 2011 TO 2014
  • JAPAN
  • TABLE 122 JAPAN PATENT LIST, 2011 TO 2014

LIST OF TABLES

  • SUMMARY TABLE GLOBAL STROKE MANAGEMENT MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 1 RISK FACTORS OF STROKE
  • TABLE 2 PREVALENCE OF STROKE IN THE U.K. BY REGION AND GENDER, 2010 (%)
  • TABLE 3 TOTAL NUMBER OF DEATHS FROM STROKE IN THE U.K. BY REGION, 2010 (NUMBER)
  • TABLE 4 ROLE OF BIOMARKERS
  • TABLE 5 BIOMARKERS FOR SPECIFIC STROKE SUBTYPES
  • TABLE 6 ADVANTAGES AND DISADVANTAGES OF BIOMARKERS BY TYPE
  • TABLE 7 POST STROKE DISEASE MANAGEMENT - CLINICAL TRIAL
  • TABLE 8 CLINICAL TRIAL: A SELF-EFFICACY ENHANCING STROKE SELF-MANAGEMENT PROGRAM FOR COMMUNITY-DWELLING STROKE SURVIVORS (SESSMP)
  • TABLE 9 CLINICAL TRIAL: ADAPTIVE PHYSICAL ACTIVITY FOR CHRONIC STROKE
  • TABLE 10 CLINICAL TRIAL: TAILORED APPROACHES TO STROKE HEALTH EDUCATION (TASHE)
  • TABLE 11 CLINICAL TRIAL: PROSPECTIVE STROKE COHORT
  • TABLE 12 HEALTHCARE EXPENDITURE COMPARISON, DEVELOPED VERSUS DEVELOPING ECONOMIES, 2008-2012* (% OF GDP)
  • TABLE 13 GLOBAL STROKE DIAGNOSTIC IMAGING MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 14 GLOBAL STROKE DIAGNOSTIC IMAGING MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 15 GLOBAL COMPUTED TOMOGRAPHY MARKET BY SYSTEM, THROUGH 2019 ($ MILLIONS)
  • TABLE 16 GLOBAL COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 17 GLOBAL SPIRAL COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 18 GLOBAL MULTISLICE COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 19 GLOBAL DUAL SOURCE MULTISLICE COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 20 GLOBAL COMPUTED TOMOGRAPHY ANGIOGRAPHY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 21 GLOBAL PERFUSION COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 22 GLOBAL MRI MARKET BY TYPES, THROUGH 2019 ($ MILLIONS)
  • TABLE 23 GLOBAL MRI MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 24 GLOBAL MAGNETIC RESONANCE ANGIOGRAPHY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 25 GLOBAL TOF-MRA MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 26 GLOBAL PC-MRA MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 27 GLOBAL CE-MRA MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 28 GLOBAL FMRI MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 29 GLOBAL PROTON MAGNETIC RESONANCE SPECTROSCOPY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 30 GLOBAL DIAGNOSTIC ULTRASOUND MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 31 GLOBAL DIAGNOSTIC ULTRASOUND MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 32 GLOBAL DOPPLER ULTRASOUND MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 33 GLOBAL DUPLEX ULTRASOUND MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 34 GLOBAL CEREBRAL ANGIOGRAPHY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 35 GLOBAL NUCLEAR IMAGING MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 36 GLOBAL NUCLEAR IMAGING MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 37 GLOBAL GAMMA CAMERA IMAGING MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 38 GLOBAL PET MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 39 GLOBAL THERAPEUTIC MANAGEMENT MARKET OF STROKE BY DRUG CATEGORY, THROUGH 2019 ($ MILLIONS)
  • TABLE 40 GLOBAL ANTICOAGULATION THERAPY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 41 GLOBAL ANTIHYPERTENSIVE DRUG THERAPY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 42 GLOBAL ANTIPLATELET DRUG THERAPY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 43 GLOBAL OTHER DRUG THERAPY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 44 GLOBAL STROKE MANAGEMENT DRUG MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 45 GLOBAL WARFARIN MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 46 GLOBAL DABIGATRAN MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 47 GLOBAL NADROPERIN MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 48 GLOBAL ENAXOPERIN MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 49 GLOBAL ATENOLOL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 50 GLOBAL METOPROLOL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 51 GLOBAL PINDOLOL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 52 GLOBAL HYDROCHLOROTHIAZIDE MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 53 GLOBAL LOSARTAN MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 54 GLOBAL ENALAPRIL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 55 GLOBAL LISINOPRIL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 56 GLOBAL FELODIPINE MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 57 GLOBAL ASPIRIN MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 58 GLOBAL DIPYRIDAMOLE MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 59 GLOBAL CLOPIDOGREL MARKET BY REGION, THROUGH 2019 ($ MILLIONS) 9
  • TABLE 60 GLOBAL STROKE RELATED SURGICAL AND ENDOVASCULAR INTERVENTIONS MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 61 GLOBAL STROKE RELATED SURGICAL AND ENDOVASCULAR INTERVENTIONS MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 62 GLOBAL STROKE-PRONE CAROTID ARTERY STENOSIS MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 63 GLOBAL STROKE-PRONE CAROTID ARTERY STENOSIS MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 64 GLOBAL CAROTID ENDARTERECTOMY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 65 GLOBAL CAROTID ARTERY STENTING MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 66 GLOBAL INTRACRANIAL ANEURYSMS AND ARTERIOVENOUS MALFORMATIONS MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 67 GLOBAL INTRACRANIAL ANEURYSMS AND ARTERIOVENOUS MALFORMATIONS MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 68 GLOBAL INTRACRANIAL ANEURYSMS MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 69 GLOBAL ARTERIOVENOUS MALFORMATIONS MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 70 GLOBAL SURGICAL REPAIR MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 71 GLOBAL ENDOVASCULAR EMBOLIZATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 72 GLOBAL STEREOTACTIC RADIOTHERAPY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 73 GLOBAL STROKES MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 74 GLOBAL HEMORRHAGIC STROKES MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 75 GLOBAL HEMORRHAGIC STROKES MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 76 GLOBAL INTRACEREBRAL STROKES MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 77 GLOBAL SUBARACHNOID HEMORRHAGE STROKES MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 78 GLOBAL ISCHEMIC STROKES MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 79 GLOBAL ISCHEMIC STROKES MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 80 GLOBAL THROMBOTIC STROKES MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 81 GLOBAL EMBOLIC STROKES MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 82 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 83 GLOBAL STROKE MANAGEMENT MARKET BY SUPPLY CHAIN MEMBERS, THROUGH 2019 ($ MILLIONS)
  • TABLE 84 GLOBAL STROKE MANAGEMENT MARKET-MANUFACTURERS, BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 85 GLOBAL STROKE MANAGEMENT MARKET-DISTRIBUTORS, BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 86 GLOBAL STROKE MANAGEMENT MARKET-SUPPLIERS, BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 87 GLOBAL STROKE MANAGEMENT MARKET BY END USERS, THROUGH 2019 ($ MILLIONS)
  • TABLE 88 GLOBAL STROKE MANAGEMENT MARKET-LIFE SCIENCES, BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 89 GLOBAL STROKE MANAGEMENT MARKET-HOSPITALS, BY SIZE, THROUGH 2019 ($ MILLIONS)
  • TABLE 90 GLOBAL STROKE MANAGEMENT MARKET-HOSPITALS, BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 91 GLOBAL STROKE MANAGEMENT MARKET-DIAGNOSTIC CENTERS, BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 92 GLOBAL STROKE MANAGEMENT MARKET-PATIENTS, BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 93 RECENT DEVELOPMENT - CERTIFICATION BY COMPANY, 2011 TO 2014
  • TABLE 94 RECENT DEVELOPMENT-PRODUCT LAUNCH BY COMPANY, 2011 TO 2014
  • TABLE 95 NORTH AMERICAN STROKE MANAGEMENT MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 96 EUROPE GERIATRIC POPULATION STATISTICS, 1991 AND 2011 (MILLIONS)
  • TABLE 97 EUROPEAN STROKE MANAGEMENT MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 98 ASIA GERIATRIC POPULATION STATISTICS, 2000 AND 2025 (MILLIONS)
  • TABLE 99 ASIAN STROKE MANAGEMENT MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 100 ROW STROKE MANAGEMENT MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 101 ABBOTT VASCULAR'S PRODUCT PORTFOLIO
  • TABLE 102 ABBOTT VASCULAR'S RECENT DEVELOPMENTS, 2011 TO AUG 2014
  • TABLE 103 B BRAUN'S PRODUCT PORTFOLIO
  • TABLE 104 BOSTON SCIENTIFIC'S PRODUCT PORTFOLIO
  • TABLE 105 BOSTON SCIENTIFIC'S RECENT DEVELOPMENTS, 2011 TO JUNE 2014
  • TABLE 106 BRISTOL MYERS SQUIBB PRODUCT PORTFOLIO
  • TABLE 107 BRISTOL MYERS SQUIBB RECENT DEVELOPMENTS - 2011 TO SEP 2014
  • TABLE 108 COAXIA INC PRODUCT PORTFOLIO
  • TABLE 109 CORDIS CORP. PRODUCT PORTFOLIO
  • TABLE 110 GE HEALTHCARE PRODUCT PORTFOLIO
  • TABLE 111 GE HEALTHCARE RECENT DEVELOPMENTS, 2011 TO AUG 2014
  • TABLE 112 GENENTECH'S PRODUCT PORTFOLIO
  • TABLE 113 GLAXOSMITHKLINE PLC PRODUCT PORTFOLIO
  • TABLE 114 MERCK'S PRODUCT PORTFOLIO
  • TABLE 115 MERCK'S RECENT DEVELOPMENTS 2011 TO SEP 2014
  • TABLE 116 MIZUHO AMERICA'S PRODUCT PORTFOLIO
  • TABLE 117 PHILIPS HEALTHCARE PRODUCT PORTFOLIO
  • TABLE 118 PHILIPS HEALTHCARE RECENT DEVELOPMENTS, 2011 TO APRIL 2014
  • TABLE 119 SIEMENS HEALTHCARE'S PRODUCT PORTFOLIO
  • TABLE 120 U.S. PATENT LIST, 2011 TO 2014
  • TABLE 121 EUROPEAN PATENT LIST, 2011 TO 2014
  • TABLE 122 JAPAN PATENT LIST, 2011 TO 2014

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL STROKE MANAGEMENT MARKET, 2013-2019 ($ MILLIONS)
  • FIGURE 1 TOP 10 LEADING CAUSES OF DEATH IN THE WORLD, 2012 (MILLIONS)
  • FIGURE 2 NUMBER OF STROKES IN THE WORLD, 1990-2010 (MILLIONS)
  • FIGURE 3 GLOBAL INCIDENCE AND PREVALENCE OF STROKE BY REGION, 2010 (%)
  • FIGURE 4 U.S. PREVALENCE OF STROKE BY AGE AND GENDER IN PERCENTAGE OF POPULATION, 2010 (%)
  • FIGURE 5 ALGORITHM FOR THE DIAGNOSIS OF ACUTE STROKE
  • FIGURE 6 SUPPLY CHAIN ANALYSIS - STROKE DIAGNOSIS AND MANAGEMENT
  • FIGURE 7 FACTORS THAT INFLUENCE THE QUALITY OF THE STROKE MANAGEMENT SUPPLY CHAIN
  • FIGURE 8 TIMELINE FOR ENACTMENT OF PRIMARY STROKE CENTER LEGISLATIVE OR NON-LEGISLATIVE POLICY, JULY 2010
  • FIGURE 9 RECENT DEVELOPMENTS BY COMPANY, 2011-2014 (NUMBER OF PROJECTS)
  • FIGURE 10 GLOBAL POPULATION GROWTH, BY AGE GROUP, 2010-2020 (MILLIONS)
  • FIGURE 11 RECENT DEVELOPMENT BY STRATEGIES, 2011 TO 2014 (NUMBER)
  • FIGURE 12 CERTIFICATION BY COMPANIES, 2011 TO 2014 (NUMBER OF CERTIFICATIONS)
  • FIGURE 13 PRODUCT LAUNCH BY COMPANIES, 2011 TO 2014 (NUMBER OF LAUNCHES)
  • FIGURE 14 GLOBAL PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)
  • FIGURE 15 U.S. PATENTS BY TECHNOLOGY, 2008 TO 2014 (NO. OF PATENTS)
  • FIGURE 16 U.S. PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)
  • FIGURE 17 EUROPEAN PATENTS BY TECHNOLOGY, 2008 TO 2014 (NO. OF PATENTS)
  • FIGURE 18 EUROPEAN PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)
  • FIGURE 19 JAPAN PATENTS BY TECHNOLOGY, 2008 TO 2014 (NO. OF PATENTS)
  • FIGURE 20 JAPAN PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)
Back to Top